<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0003002'>Breast cancer</z:hpo> is commonly diagnosed in postmenopausal women, the majority of whom express 1 or more <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> risk factors </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">Cardiovascular disease</z:e> poses a significant competing risk for morbidity and mortality among nonmetastatic <z:hpo ids='HP_0003002'>breast cancer</z:hpo> survivors </plain></SENT>
<SENT sid="2" pm="."><plain>Adjuvant systemic therapies may result in late-cardiac toxicity decades after treatment completion </plain></SENT>
<SENT sid="3" pm="."><plain>The cumulative incidence of treatment-related cardiotoxic outcomes may be as high as 33% after some adjuvant <z:hpo ids='HP_0003002'>breast cancer</z:hpo> therapies </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0003002'>Breast cancer</z:hpo> treatment-induced cardiotoxicity may manifest as <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo>, coronary <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, <z:hpo ids='HP_0001907'>thromboembolism</z:hpo>, <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> and conduction abnormalities, and valvular and <z:e sem="disease" ids="C0265122" disease_type="Disease or Syndrome" abbrv="">pericardial disease</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Evidence indicates that preexisting cardiovascular conditions such as <z:hpo ids='HP_0000822'>hypertension</z:hpo> or left ventricular dysfunction may compound the adverse effects of cardiotoxic treatments </plain></SENT>
<SENT sid="6" pm="."><plain>There are currently no published clinical practice guidelines that address ongoing cardiac surveillance for cardiotoxicity after <z:hpo ids='HP_0003002'>breast cancer</z:hpo>, and existing guidelines for monitoring and promoting cardiovascular health in older women are often not followed </plain></SENT>
<SENT sid="7" pm="."><plain>The multidisciplinary prospective surveillance system proposed elsewhere in this supplement would allow for earlier detection of cardiotoxicity from treatment and may improve monitoring of cardiovascular health in the growing population of <z:hpo ids='HP_0003002'>breast cancer</z:hpo> survivors </plain></SENT>
</text></document>